Uttarakhand News Today

Alzheimer’s Disease Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Alzheimer’s Disease Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 26
08:04 2023
Alzheimer’s Disease Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Alzheimer’s Disease Pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Alzheimer’s Disease NDA approvals (if any), and product development activities comprising the technology, Alzheimer’s Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Alzheimer’s Disease Pipeline Insight Report

  • DelveInsight’s Alzheimer’s Disease Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Alzheimer’s Disease.
  • The leading Alzheimer’s Disease Companies such as Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others are developing potential drug candidates to boost the Alzheimer’s Disease treatment scenario.
  • Alzheimer’s Disease pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

To explore more information on the latest breakthroughs in the Alzheimer’s Disease Pipeline treatment landscape of the report, click here @ Alzheimer’s Disease Pipeline Outlook

 

Alzheimer’s Disease Overview

Alzheimer’s Disease is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer’s disease are the accumulation of the protein fragment beta‐amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.

 

Recent Breakthroughs of Alzheimer’s Disease Treatment Landscape

  • In February 2021, NeurMedix announced that it had received authorization from the U.S. Food and Drug Administration’s (FDA) Office of Neuroscience, Division of Neurology I, to initiate a pivotal phase 3 clinical trial in Alzheimer’s Disease with its lead clinical drug candidate, NE3107.
  • In December 2019, BioArctic declared the initiation of a research deal with Eisai to investigate further the unique profile of the investigational drug candidate BAN2401.
  • In June 2020, Eli Lilly and Company initiated TRAILBLAZER-ALZ 2, a Phase III clinical study of Donanemab for the treatment of Alzheimer Disease. The study is expected to be completed by December 2023, with an estimated enrollment of 1500 participants.

 

Request a sample and discover the recent advances in Alzheimer’s Disease Ongoing Clinical Trial Analysis and Medications, click here @ Alzheimer’s Disease Treatment Landscape

 

Alzheimer’s Disease Emerging Drugs Profile

 BAN2401: Eisai

BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic Aβ protofibrils that are thought to be a causative factor for Alzheimer’s Disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007.

 

 Gantenerumab: Hoffmann-La Roche

Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.

 

Alzheimer’s Disease Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Alzheimer’s Disease (AD). The companies which have their Alzheimer’s Disease (AD) drug candidates in the most advanced stage, i.e. phase III include, Eisai.

 

Scope of the Alzheimer’s Disease Pipeline Report

  • Coverage- Global
  • Alzheimer’s Disease Therapeutics Assessment: Product Type, Molecule Type, Mechanism of Action, Route of Administration
  • Alzheimer’s Disease Companies: Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and many others.  

 

Table of Content

  1. Introduction
  2. Alzheimer’s Disease Executive Summary
  3. Alzheimer’s Disease Overview
  4. Alzheimer’s Disease Pipeline Therapeutics
  5. Alzheimer’s Disease Pipeline Therapeutic Assessment
  6. Alzheimer’s Disease – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Alzheimer’s Disease Collaboration Deals
  9. Late Stage Products (Phase III)
  10. BAN2401: Eisai
  11. Mid Stage Products (Phase II)
  12. Bryostatin-1: Neurotrope
  13. Early Stage Products (Phase I)
  14. INB03 – INmune Bio
  15. Pre-clinical and Discovery Stage Products
  16. AZT-211: AZTherapies
  17. Inactive Products
  18. Alzheimer’s Disease Key Companies
  19. Alzheimer’s Disease Key Products
  20. Alzheimer’s Disease- Unmet Needs
  21. Alzheimer’s Disease- Market Drivers and Barriers
  22. Alzheimer’s Disease- Future Perspectives and Conclusion
  23. Alzheimer’s Disease Analyst Views
  24. Alzheimer’s Disease Key Companies
  25. Appendix

 

Got Queries? Find out the related information on Alzheimer’s Disease Mergers and acquisitions, Alzheimer’s Disease Licensing Activities @ Alzheimer’s Disease Emerging Drugs, and Recent Trends

 

Trending Reports- Stem Cell Market | Asperger Syndrome Market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles